Axovant Sciences Ltd (NASDAQ:AXON) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $1.45 and last traded at $1.62, with a volume of 264900 shares trading hands. The stock had previously closed at $1.62.
AXON has been the topic of a number of recent research reports. Jefferies Group downgraded shares of Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research note on Thursday, December 21st. Cowen downgraded shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research note on Friday, January 12th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Axovant Sciences in a research note on Friday, December 1st. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Wednesday, January 31st. Finally, ValuEngine downgraded shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Axovant Sciences presently has an average rating of “Hold” and an average price target of $13.61.
The company has a market cap of $155.10 and a P/E ratio of -0.61. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 0.45.
ILLEGAL ACTIVITY WARNING: “Axovant Sciences (AXON) Reaches New 52-Week Low at $1.45” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3220433/axovant-sciences-axon-sets-new-52-week-low-at-1-45.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.